More than 45 organizations, including the AHA, today encouraged members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974), which the panel is expected to consider next week. The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs,” the organizations said in a letter to committee leaders. “The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over 10 years. We sincerely thank you and your colleagues who have supported the CREATES Act, and we encourage all members of the Committee to vote in favor of the bill.” 

Related News Articles

Headline
The House June 4 passed the AHA-supported SUPPORT Act (H.R. 2483) by a 366-57 vote. The legislation reauthorizes key prevention, treatment and recovery…
Headline
Sens. Chuck Schumer, D-N.Y., Susan Collins, R-Maine, and Andy Kim, D-N.J., June 5 reintroduced the SEPSIS Act, legislation which would task the Centers for…
Perspective
Public
After approval in the House last week by a one vote margin, the One Big Beautiful Bill Act — a sweeping package that would enact many of President Trump’s…
Headline
AHA May 23 submitted recommendations to the Department of Justice and Federal Trade Commission in response to the agencies’ requests for information on…
Headline
The House Budget Committee May 18 advanced the fiscal year 2025 budget reconciliation bill by a 17-16 vote along party lines, as four Republicans who…
Headline
The House Energy and Commerce Committee today advanced by a 30-24 vote along party lines its portion of the fiscal year 2025 reconciliation bill following a…